tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jan 21;10(2):158.
doi: 10.3390/vaccines10020158.
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
Marika Watanabe[SUP] 1 [/SUP], Kimikazu Yakushijin[SUP] 1 [/SUP], Yohei Funakoshi[SUP] 1 [/SUP], Goh Ohji[SUP] 2 [/SUP], Wataru Hojo[SUP] 3 [/SUP], Hironori Sakai[SUP] 3 [/SUP], Miki Saeki[SUP] 1 [/SUP], Yuri Hirakawa[SUP] 1 [/SUP], Sakuya Matsumoto[SUP] 1 [/SUP], Rina Sakai[SUP] 1 [/SUP], Shigeki Nagao[SUP] 1 [/SUP], Akihito Kitao[SUP] 1 [/SUP], Yoshiharu Miyata[SUP] 4 [/SUP], Taiji Koyama[SUP] 1 [/SUP], Yasuyuki Saito[SUP] 5 [/SUP], Shinichiro Kawamoto[SUP] 1 [/SUP], Mitsuhiro Ito[SUP] 1 6 [/SUP], Tohru Murayama[SUP] 1 7 [/SUP], Hiroshi Matsuoka[SUP] 4 [/SUP], Hironobu Minami[SUP] 1 8 [/SUP]
Affiliations
Abstract
Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.
Keywords: BNT162b2; COVID-19; hematopoietic stem cell transplantation; vaccination.
. 2022 Jan 21;10(2):158.
doi: 10.3390/vaccines10020158.
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
Marika Watanabe[SUP] 1 [/SUP], Kimikazu Yakushijin[SUP] 1 [/SUP], Yohei Funakoshi[SUP] 1 [/SUP], Goh Ohji[SUP] 2 [/SUP], Wataru Hojo[SUP] 3 [/SUP], Hironori Sakai[SUP] 3 [/SUP], Miki Saeki[SUP] 1 [/SUP], Yuri Hirakawa[SUP] 1 [/SUP], Sakuya Matsumoto[SUP] 1 [/SUP], Rina Sakai[SUP] 1 [/SUP], Shigeki Nagao[SUP] 1 [/SUP], Akihito Kitao[SUP] 1 [/SUP], Yoshiharu Miyata[SUP] 4 [/SUP], Taiji Koyama[SUP] 1 [/SUP], Yasuyuki Saito[SUP] 5 [/SUP], Shinichiro Kawamoto[SUP] 1 [/SUP], Mitsuhiro Ito[SUP] 1 6 [/SUP], Tohru Murayama[SUP] 1 7 [/SUP], Hiroshi Matsuoka[SUP] 4 [/SUP], Hironobu Minami[SUP] 1 8 [/SUP]
Affiliations
- PMID: 35214617
- DOI: 10.3390/vaccines10020158
Abstract
Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.
Keywords: BNT162b2; COVID-19; hematopoietic stem cell transplantation; vaccination.